atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today reported its financial results for the third quarter ended September 30, 2021, and provided its corporate update. “Following our IPO in June, we continue to see positive momentum. We have 11 therapeutic programs underway and…